Trusted Press Release Distribution   Join | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Precision Business Insights
www.precisionbusinessinsights.com
Rajesh k
sales@precisionbusinessinsights.com
Precision Business Insights, Kemp House, 152 – 160 City Road,
EC1V 2NX

Bookmark and Share
Antimicrobial Peptides Market: Market Size, Share, Report, Research, Forecast 2018 to 2024
Global Antimicrobial Peptides Market: Market Estimation, Dynamics, Trends, Competitor Analysis, and Forecast 2018 to 2024


Antimicrobial Peptide...
BriefingWire.com, 5/18/2018 - The soaring drug-resistant infections have projected a serious challenge to the antimicrobial therapies. The Centers for Disease Control reports that each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics. At least 23,000 people die each year as a direct result of these infections. Antimicrobial peptides (AMPs) are also known as host defense peptides. They are short and usually positively charged peptides found in various life forms. The antimicrobial peptides have the ability to kill microbial pathogens directly. They are considered as the potential therapeutic sources of future antibiotics.

Free sample of this report is available upon request @

www.precisionbusinessinsights.com/market-reports/antimicrobial-peptides-market/#ulp-4H8Z4LpNMLEuOnnx

? In February 2017, Symcel has partnered with Colzyx to test 25 new collagen VI-derived antimicrobial peptides in order to analyze their capability to halt bacterial growth.

o The collagen VI-derived peptides test is performed using Symcel’s CalScreener. The Symcel technology is flexible to test each peptide independently or in combination with others.

? As per the research conducted by Anne Kokel et al recent strategies were reported for improving AMPs in the context of drug design and delivery were surveyed, and also their possible impact on patients and the environment was assessed

• In the research, it is found that AMPs are considered to lack selectivity leading to side effects and cytotoxicity, and also exhibit in vivo instability. Several strategies are being actively considered to overcome the limitations that restrain the success of AMPs.

Free TOC of this report is available upon request @

www.precisionbusinessinsights.com/market-reports/antimicrobial-peptides-market/#ulp-c654SbFYO64MsOhu

? University of Pittsburgh Innovation Institute – has conducted a research on the A4-antimicrobial peptides (A4-AMPs)

o As per the research, A4-antimicrobial peptides (A4-AMPs) are a new class of peptide-based antibiotic that kills more than 90% of antibiotic-resistant species of bacteria. The study also says that A4 has a novel mechanism-of-action that does not confer resistance easily.

Need more information about this report @

www.precisionbusinessinsights.com/market-reports/antimicrobial-peptides-market/#ulp-14mlyhjMGhVjZqa3

? As per the study conducted by Abdurraouf Zaet et al over D-Cateslytin, a new antimicrobial peptide

o D- Cateslytin has emerged as a potent, safe and robust peptide antimicrobial with undetectable susceptibility to resistance

o Using Escherichia coli as the model in the study, it was observed that D-Ctl targets the bacterial cell wall leading to the permeabilization of the membrane and the death of the bacteria

o The results obtained by the study has shown that:

? D-Ctl is an efficient antimicrobial agent against various bacterial strains

? D-Ctl is a potentiator for numerous antimicrobials

? Unlike ampicillin and cefotaxime, D-Ctl does not trigger resistance in E. coli

Get access to full summary @

www.precisionbusinessinsights.com/market-reports/antimicrobial-peptides-market/

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2013 Proserve Technology, Inc.